Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a single-blind, parallel-group, randomized pilot study designed to evaluate and
compare the efficacy of 3 different mouthwashes containing 0.2% Chlorhexidine digluconate,
1.5% Hydroxide peroxide or Cetylpyridinium chloride in reducing Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) viral load in the saliva of COVID-19 positive patients at
different time-points.
A convenient sample of up to 40 COVID-19 positive patients diagnosed via test and/or
presenting COVID-19 clinical symptoms will be identified in the inpatients and/or outpatient
clinics at the Newham University Hospital and at The Royal London Hospital, Barts Health
National Health Service (NHS) Trust, United Kingdom (UK).
The study will consist of one visit. Unstimulated saliva samples will be collected from all
COVID-19 positive patients before and at 30 minutes, 1, 2, and 3 hours after mouth rinsing
(Group 1-3 ) or no rinsing (Group 4). Viral load analysis of saliva samples in the different
time-points will be then assessed by Reverse Transcription quantitative PCR (RT- qPCR).